Events

Info session: Digital Europe - First 2025 calls
APR
Mon
14
10:00 - 13:00

This was 1 month ago

Location

Hybrid - Brussels and online

Hoek38
Leuvenseweg 38
1000 Brussels
Programmes
Digital Europe AI Continent Cybersecurity Advanced Digital Skills Deployment: Best use of technologies European Digital Innovation Hubs

The recording of the event is available in the video corner.

The Digital Europe Main Work Programme 2025-2027 and the Digital Europe Cybersecurity Work Programme 2025-2027 have been published, the first call open in April. 

NCP Flanders, in cooperation with Department WEWIS, organises an info session to provide information on the context and content of the programme and the first round of 2025 calls, participation requirements and the support NCP Flanders can give to interested stakeholders.

On the agenda:

  • Digital Europe Policy Background
  • How to participate? Legal and financial requirements of Digital Europe
  • What’s in it this time? First calls of 2025 and outlook until 2027
  • Inspiration: examples of current projects
  • Tips & tricks for a good proposal and NCP support

Registration is free, but mandatory via this link.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.